Early Treatment Benefits of Telmisartan Combination Therapy for Hypertension

A recent review highlights the advantages of early use of single-pill combinations (SPCs) in hypertension management, focusing on telmisartan/amlodipine (T/A) and telmisartan/hydrochlorothiazide (T/H). Compared with monotherapies, both once-daily SPCs deliver greater blood pressure reductions, higher goal achievement, and improved response rates across all hypertension stages. Subgroup analyses confirm consistent efficacy regardless of age, race, or comorbidities such as diabetes, obesity, or renal impairment. The T/A combination shows superior 24-hour blood pressure control with fewer cases of edema than amlodipine alone, while the T/H combination demonstrates stronger late-hour blood pressure control with lower rates of hypokalemia than hydrochlorothiazide alone. Evidence supports T/A use in patients with diabetes or metabolic syndrome, and T/H use in patients requiring volume reduction or with edema.